News

The oral therapy may address limitations including difficulty in application and adverse events with topical therapies.

According to Phase 3 LIBERTY-CUPID trial results, dupilumab significantly reduces itch and hive activity from baseline in chronic spontaneous urticaria.

In this Month in Review summary, some of the most notable advancements and developments in the field of dermatology were highlighted.

Clinical images help pathologists improve diagnostic confidence and agreement, leading to more accurate diagnoses of melanocytic skin lesions.

Risankizumab achieves significantly higher rates of skin clearance and improved quality of life versus deucravacitinib in matching-adjusted indirect comparison analysis.

New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.

The approval by the FDA of minocycline hydrochloride modified release capsules, also known as DFD-29, will allow for treatment of inflammatory lesions and erythema among adults.

In this analysis, investigators identified several markers such as monocyte-high-density lipoprotein cholesterol ratio and C-reactive protein values.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

Neither clinician peer comparison nor patient informational mail reduced benzodiazepine use among older adults in anesthesia care, a new study finds.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

The biosimilars month in review highlights new approvals, new safety findings, and new cost savings with biosimilars.

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

T-VASI and F-VASI are validated, responsive tools for assessing vitiligo severity and re-pigmentation, with meaningful change thresholds established.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.